{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T15:08:18Z","timestamp":1785683298486,"version":"3.56.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["18122013"],"award-info":[{"award-number":["18122013"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ex vivo drug screening refers to the out-of-body assessment of drug efficacy in patient derived vital tumor cells. The purpose of these methods is to enable functional testing of patient specific efficacy of anti-cancer therapeutics and personalized treatment strategies. Such approaches could prove powerful especially in context of rare cancers for which demonstration of novel therapies is difficult due to the low numbers of patients. Here, we report comparison of different ex vivo drug screening methods in a metastatic urachal adenocarcinoma, a rare and aggressive non-urothelial bladder malignancy that arises from the remnant embryologic urachus in adults.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To compare the feasibility and results obtained with alternative ex vivo drug screening techniques, we used three different approaches; enzymatic cell viability assay of 2D cell cultures and image-based cytometry of 2D and 3D cell cultures in parallel. Vital tumor cells isolated from a biopsy obtained in context of a surgical debulking procedure were used for screening of 1160 drugs with the aim to evaluate patterns of efficacy in the urachal cancer cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Dose response data from the enzymatic cell viability assay and the image-based assay of 2D cell cultures showed the best consistency. With 3D cell culture conditions, the proliferation rate of the tumor cells was slower and potency of several drugs was reduced even following growth rate normalization of the responses. MEK, mTOR, and MET inhibitors were identified as the most cytotoxic targeted drugs. Secondary validation analyses confirmed the efficacy of these drugs also with the new human urachal adenocarcinoma cell line (MISB18) established from the patient\u2019s tumor.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>All the tested ex vivo drug screening methods captured the patient\u2019s tumor cells\u2019 sensitivity to drugs that could be associated with the oncogenic KRAS<jats:sup>G12V<\/jats:sup> mutation found in the patient\u2019s tumor cells. Specific drug classes however resulted in differential dose response profiles dependent on the used cell culture method indicating that the choice of assay could bias results from ex vivo drug screening assays for selected drug classes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-020-07092-w","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T12:03:18Z","timestamp":1592913798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma"],"prefix":"10.1186","volume":"20","author":[{"given":"Rami","family":"M\u00e4kel\u00e4","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Arjonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ville","family":"H\u00e4rm\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Rintanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauri","family":"Paasonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Paprotka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"R\u00f6nsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teijo","family":"Kuopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Kononen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4999-5585","authenticated-orcid":false,"given":"Juha K.","family":"Rantala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,23]]},"reference":[{"issue":"4","key":"7092_CR1","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.eururo.2019.06.016","volume":"76","author":"K Kettunen","year":"2019","unstructured":"Kettunen K, Bostr\u00f6m PJ, Lamminen T, et al. Personalized drug sensitivity screening for bladder cancer using conditionally reprogrammed patient-derived cells. Eur Urol. 2019;76(4):430\u20134.","journal-title":"Eur Urol"},{"issue":"11","key":"7092_CR2","doi-asserted-by":"publisher","first-page":"5867","DOI":"10.21873\/anticanres.13791","volume":"39","author":"KI Lehtomaki","year":"2019","unstructured":"Lehtomaki KI, Lahtinen LI, Rintanen N, et al. Clonal evolution of MEK\/MAPK pathway activating mutations in a metastatic colorectal cancer case. Anticancer Res. 2019;39(11):5867\u201377.","journal-title":"Anticancer Res"},{"key":"7092_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.lungcan.2020.04.036","volume":"145","author":"A Arjonen","year":"2020","unstructured":"Arjonen A, M\u00e4kel\u00e4 R, H\u00e4rm\u00e4 V, et al. Image-based ex vivo drug screen to assess targeted therapies in recurrent thymoma. Lung Cancer. 2020;145:27\u201332.","journal-title":"Lung Cancer"},{"key":"7092_CR4","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1016\/S1470-2045(15)00396-4","volume":"17","author":"L Billingham","year":"2016","unstructured":"Billingham L, Malottki K, Steven N. Research methods to change clinical practice for patients with rare cancers. Lancet Oncol. 2016;17:e70\u201380.","journal-title":"Lancet Oncol"},{"issue":"5","key":"7092_CR5","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/2159-8290.CD-16-1154","volume":"7","author":"C Pauli","year":"2017","unstructured":"Pauli C, Hopkins BD, Prandi D, et al. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discov. 2017;7(5):462\u201377.","journal-title":"Cancer Discov"},{"issue":"2","key":"7092_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/PAP.0000000000000110","volume":"23","author":"GP Paner","year":"2016","unstructured":"Paner GP, Lopez-Beltran A, Sirohi D, Amin MB. Updates in the pathologic diagnosis and classification of epithelial neoplasms of urachal origin. Adv Anat Pathol. 2016;23(2):71\u201383.","journal-title":"Adv Anat Pathol"},{"key":"7092_CR7","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/PAS.0b013e31819aa4ae","volume":"33","author":"A Gopalan","year":"2009","unstructured":"Gopalan A, Sharp DS, Fine SW, et al. Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol. 2009;33:659\u201368.","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"7092_CR8","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/cncr.22060","volume":"107","author":"RA Ashley","year":"2006","unstructured":"Ashley RA, Inman BA, Sebo TJ, Leibovich BC, Blute ML, Kwon ED, et al. Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer. 2006;107(4):712\u201320.","journal-title":"Cancer."},{"key":"7092_CR9","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1159\/000362400","volume":"59","author":"Y Yanagihara","year":"2013","unstructured":"Yanagihara Y, Tanji N, Miura N, et al. Modified FOLFOX6 chemotherapy in patients with metastatic urachal cancer. Chemotherapy. 2013;59:402\u20136.","journal-title":"Chemotherapy."},{"issue":"1","key":"7092_CR10","doi-asserted-by":"publisher","first-page":"33.e11","DOI":"10.1016\/j.urolonc.2016.07.021","volume":"35","author":"KS Mylonas","year":"2017","unstructured":"Mylonas KS, Malley PO, Ziogas IA, El-Kabab L, Nasioudis D. Malignant urachal neoplasms: a population-based study and systematic review of literature. Urol Oncol. 2017;35(1):33.e11\u20139.","journal-title":"Urol Oncol"},{"key":"7092_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/iju.14154","volume":"2","author":"Y Nagumo","year":"2020","unstructured":"Nagumo Y, Kojima T, Shiga M, et al. Clinicopathological features of malignant urachal tumor: a hospital-based cancer registry data in Japan. Int J Urol. 2020;2:157\u201362.","journal-title":"Int J Urol"},{"key":"7092_CR12","first-page":"E57","volume":"3","author":"Z Hamilou","year":"2020","unstructured":"Hamilou Z, North S, Canil C, et al. Management of urachal cancer: a consensus statement by the Canadian Urological Association and genitourinary medical oncologists of Canada. Can Urol Assoc J. 2020;3:E57\u201364.","journal-title":"Can Urol Assoc J"},{"issue":"9","key":"7092_CR13","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.urolonc.2016.04.012","volume":"34","author":"T Szarvas","year":"2016","unstructured":"Szarvas T, M\u00f3dos O, Niedworok C, Reis H, Szendr\u00f6i A, Sz\u00e1sz MA, et al. Clinical, prognostic, and therapeutic aspects of urachal carcinoma-a comprehensive review with meta-analysis of 1,010 cases. Urol Oncol. 2016;34(9):388\u201398.","journal-title":"Urol Oncol"},{"issue":"2","key":"7092_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.eucr.2014.11.004","volume":"3","author":"T Kanamaru","year":"2015","unstructured":"Kanamaru T, Iguchi T, Yukimatsu N, Shimizu Y, Kohyama Y, Tachibana H, et al. A case of metastatic urachal carcinoma treated with FOLFIRI (irinotecan and 5-fluorouracil\/leucovorin) plus bevacizumab. Urol Case Rep. 2015;3(2):9\u201311.","journal-title":"Urol Case Rep"},{"issue":"2","key":"7092_CR15","first-page":"5120","volume":"17","author":"B Tran","year":"2010","unstructured":"Tran B, McKendrick J. Metastatic urachal cancer responding to FOLFOX chemotherapy. Can J Urol. 2010;17(2):5120\u20133.","journal-title":"Can J Urol"},{"issue":"2","key":"7092_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000334414","volume":"88","author":"S Yazawa","year":"2012","unstructured":"Yazawa S, Kikuchi E, Takeda T, et al. Surgical and chemotherapeutic options for urachal carcinoma: report of ten cases and literature review. Urol Int. 2012;88(2):209\u201314.","journal-title":"Urol Int"},{"key":"7092_CR17","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/j.1442-2042.2007.01855.x","volume":"14","author":"SH Hong","year":"2007","unstructured":"Hong SH, Kim JC, Hwang TK. Laparoscopic partial cystectomy with en bloc resection of the urachus for urachal adenocarcinoma. Int J Urol. 2007;14:963\u20135.","journal-title":"Int J Urol"},{"key":"7092_CR18","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.ejso.2019.03.034","volume":"45","author":"LS Mertens","year":"2019","unstructured":"Mertens LS, Behrendt MA, Mehta AM, et al. Long-term survival after cytoreductive surgery and hyperthermicintraperitoneal chemotherapy (HIPEC) for patients with peritonealmetastases of urachal cancer. Eur J Surg Oncol. 2019;45:1740\u20134.","journal-title":"Eur J Surg Oncol"},{"key":"7092_CR19","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1097\/01.ju.0000054646.49381.01","volume":"169","author":"AO Siefker-Radtke","year":"2003","unstructured":"Siefker-Radtke AO, Gee J, Shen Y, et al. Multimodality management of urachal carcinoma: the M. D. Anderson cancer center experience. J Urol. 2003;169:1295\u20138.","journal-title":"J Urol"},{"issue":"11","key":"7092_CR20","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1002\/cncr.23070","volume":"110","author":"JR Molina","year":"2007","unstructured":"Molina JR, Quevedo JF, Furth AF, Richardson RL, Zincke H, Burch PA. Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases. Cancer. 2007;110(11):2434\u201340.","journal-title":"Cancer."},{"key":"7092_CR21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.humpath.2013.09.008","volume":"45","author":"SJ Sirintrapun","year":"2014","unstructured":"Sirintrapun SJ, Ward M, Woo J, et al. High-stage urachal adenocarcinoma can be associated with microsatellite instability and KRAS mutations. Hum Pathol. 2014;45:327\u201330.","journal-title":"Hum Pathol"},{"issue":"5","key":"7092_CR22","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.eururo.2016.04.037","volume":"70","author":"A Collazo-Lorduy","year":"2016","unstructured":"Collazo-Lorduy A, Castillo-Martin M, Wang L, et al. Urachal carcinoma shares genomic alterations with colorectal carcinoma and may respond to epidermal growth factor inhibition. Eur Urol. 2016;70(5):771\u20135.","journal-title":"Eur Urol"},{"issue":"7","key":"7092_CR23","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/ijc.31547","volume":"143","author":"H Reis","year":"2018","unstructured":"Reis H, van der Vos KE, Niedworok C, et al. Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas. Int J Cancer. 2018;143(7):1764\u201373.","journal-title":"Int J Cancer"},{"issue":"4","key":"7092_CR24","doi-asserted-by":"publisher","first-page":"e449","DOI":"10.1016\/j.clgc.2016.03.013","volume":"14","author":"KP Loh","year":"2016","unstructured":"Loh KP, Mondo E, Hansen EA, et al. Targeted therapy based on tumor genomic analyses in metastatic urachal carcinoma. Clin Genitourin Cancer. 2016;14(4):e449\u201352.","journal-title":"Clin Genitourin Cancer"},{"issue":"8","key":"7092_CR25","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1002\/1878-0261.12326","volume":"12","author":"S Doll","year":"2018","unstructured":"Doll S, Kriegmair MC, Santos A, et al. Rapid proteomic analysis for solid tumors reveals LSD1 as a drug target in an end-stage cancer patient. Mol Oncol. 2018;12(8):1296\u2013307.","journal-title":"Mol Oncol"},{"issue":"26","key":"7092_CR26","doi-asserted-by":"publisher","first-page":"39293","DOI":"10.18632\/oncotarget.9828","volume":"7","author":"O M\u00f3dos","year":"2016","unstructured":"M\u00f3dos O, Reis H, Niedworok C, et al. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance. Oncotarget. 2016;7(26):39293\u2013301.","journal-title":"Oncotarget."},{"issue":"D1","key":"7092_CR27","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum MJ, Lee JM, Benson M, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46(D1):D1062\u20137.","journal-title":"Nucleic Acids Res"},{"key":"7092_CR28","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou\u2013Talalay method. Cancer Res. 2010;70:440\u20136.","journal-title":"Cancer Res"},{"key":"7092_CR29","doi-asserted-by":"publisher","first-page":"e230215","DOI":"10.1136\/bcr-2019-230215","volume":"12","author":"KK Sahu","year":"2019","unstructured":"Sahu KK, Pandey D, Mishra AK, et al. Mystery of neck lump: an uncommon presentation of urachal cancer. BMJ Case Rep. 2019;12:e230215.","journal-title":"BMJ Case Rep"},{"key":"7092_CR30","first-page":"50011","volume":"71","author":"MA Labarge","year":"2013","unstructured":"Labarge MA, Garbe JC, Stampfer MR. Processing of human reduction mammoplasty and mastectomy tissues for cell culture. J Vis Exp. 2013;71:50011.","journal-title":"J Vis Exp"},{"key":"7092_CR31","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.7164\/antibiotics.34.1248","volume":"34","author":"JW Westley","year":"1981","unstructured":"Westley JW, Evans RH Jr, Sello LH, Troupe N, Liu C, Miller PA. Isolation of novel antibiotics X 14667A and X-14667B from Streptomyces cinnamonensis subsp. urethanofaciens and their characterization as 2-phenethylurethanes of monensins B and a. J Antibiot (Tokyo). 1981;34:1248\u201352.","journal-title":"J Antibiot (Tokyo)"},{"issue":"12","key":"7092_CR32","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1158\/1535-7163.MCT-10-0368","volume":"9","author":"K Ketola","year":"2010","unstructured":"Ketola K, Vainio P, Fey V, Kallioniemi O, Iljin K. Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells. Mol Cancer Ther. 2010;9(12):3175\u201385.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"7092_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cels.2019.06.005","volume":"9","author":"M Niepel","year":"2019","unstructured":"Niepel M, Hafner M, Mills CE, et al. A multi-center study on the reproducibility of drug-response assays in mammalian cell lines. Cell Syst. 2019;9(1):35\u201348.e5.","journal-title":"Cell Syst"},{"key":"7092_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells9010198","volume":"9","author":"U Degirmenci","year":"2020","unstructured":"Degirmenci U, Wang M, Hu J. Targeting aberrant RAS\/RAF\/MEK\/ERK signaling for cancer therapy. Cells. 2020;9:1.","journal-title":"Cells"},{"issue":"3","key":"7092_CR35","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1158\/2159-8290.CD-16-0653","volume":"7","author":"JS Zawistowski","year":"2017","unstructured":"Zawistowski JS, Bevill SM, Goulet DR, et al. Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex. Cancer Discov. 2017;7(3):302\u201321.","journal-title":"Cancer Discov"},{"issue":"8","key":"7092_CR36","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrd4694","volume":"14","author":"A Mullard","year":"2015","unstructured":"Mullard A. NCI-MATCH trial pushes cancer umbrella trial paradigm. Nat Rev Drug Discov. 2015;14(8):513\u20135.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"7092_CR37","doi-asserted-by":"publisher","first-page":"e595","DOI":"10.1016\/S2352-3026(17)30208-9","volume":"4","author":"B Snijder","year":"2017","unstructured":"Snijder B, Vladimer GI, Krall N, et al. Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. Lancet Haematol. 2017;4(12):e595\u2013606.","journal-title":"Lancet Haematol"},{"issue":"1","key":"7092_CR38","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1038\/s41467-018-04495-z","volume":"9","author":"L Puca","year":"2018","unstructured":"Puca L, Bareja R, Prandi D, et al. Patient derived organoids to model rare prostate cancer phenotypes. Nat Commun. 2018;9(1):2404.","journal-title":"Nat Commun"},{"issue":"9","key":"7092_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183074","volume":"12","author":"M Jeppesen","year":"2017","unstructured":"Jeppesen M, Hagel G, Glenthoj A, et al. Short-term spheroid culture of primary colorectal cancer cells as an in vitro model for personalizing cancer medicine. PLoS One. 2017;12(9):e0183074.","journal-title":"PLoS One"},{"issue":"1","key":"7092_CR40","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/s41598-017-01566-x","volume":"7","author":"N Brijwani","year":"2017","unstructured":"Brijwani N, Jain M, Dhandapani M, et al. Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on notch and Erbb2. Sci Rep. 2017;7(1):1502.","journal-title":"Sci Rep"},{"issue":"6","key":"7092_CR41","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41416-019-0672-6","volume":"122","author":"IR Powley","year":"2020","unstructured":"Powley IR, Patel M, Miles G, et al. Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery. Br J Cancer. 2020;122(6):735 Epub ahead of print.","journal-title":"Br J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07092-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07092-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07092-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T18:04:03Z","timestamp":1650218643000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07092-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7092"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07092-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,23]]},"assertion":[{"value":"6 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Review Board of the Central Finland Health Care District. The use and investigation of the patient derived cells was conducted in accordance with approval by the local Ethics Committee of the Central Finland Health Care District (KSSHP 3\u2009U\/2015). All experiments were undertaken with the understanding and written informed consent of the patient. The study methodologies conformed to the standards set by the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors of this manuscript declare that they have no competing interests. Juha K. Rantala is the founder of Misvik Biology Oy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"590"}}